NKTR Stock Analysis: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$65.71
-2.56 (-3.74%)
▼
5d:
-3.83%
30d:
+7.85%
90d:
-22.57%
BUY
HIGH Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 06, 2026
16d
Smart Money Distribution
None View Scanner →
Strength: 5.7/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NKTR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NKTR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $65.70, which is considered fair relative to its 30-day fair value range of $61.85 to $70.72.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $64.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $153.25 (+124.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NKTR is in a strong uptrend. The price is currently testing key support at $64.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $153.25 (+124.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$61.85 -
$70.72
Company Quality Score
52/100
(HOLD)
Options IV Signal
13th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 13th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 124.5% below Wall St target ($153.25)
Trading Range Analysis
30-Day Trading Range
$61.85 -
$70.72
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$6.11
(9.3%)
Support & Resistance Levels
Support Level
$64.46
Resistance Level
$77.23
Current Trend
Strong Uptrend
Technical data as of
Jul 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.43
Wall Street Target
$153.25
(+124.5%)
Revenue Growth (YoY)
3.8%
Profit Margin
-284.2%
Share & Embed Analysis
Last updated: July 20, 2026 2:04 PM ET
Data refreshes hourly during market hours. Next update: 3:04 PM
Data refreshes hourly during market hours. Next update: 3:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Zalevsky
SELL
180 shares
2026-02-18
Howard W Robin
SELL
423 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 49 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$819 | 69 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$125 | 60 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$262 | 63 BUY |
